Barriers to current DMARD use from pts, discussed during routine visits were primarily related to side effects and concerns about the efficacy and long-term use. Continuous attention to these patients’ concerns are key to better treatment adherence https://t.co/J0kPR2CQyH https://t.co/D84t4dPdLO

• https://buff.ly/huWAZmP

Patient Education handout on Raynaud’s Phenomenon https://t.co/cm77mmmPSi https://t.co/GimQXHBdpp

• Raynaud’s Phenomenon: When Cold Hands Reveal Hidden Disease

“Medicine is a science of uncertainty and an art of probability.” - Sir William Osler https://t.co/SQH3JZcDfv

Targeting Obesity in Rheumatic Disease Patients Sattar et al. has published an informative overview of the effect of obesity on rheumatic and musculoskeletal diseases (RMDs). They estimate that nearly 70% of RMD patients are overweight or obese. https://t.co/OYtsbfJQ2e https://t.co/xEZI3mkY0q

• Targeting Obesity in Rheumatic Disease Patients | RheumNow

Disease activity during Pregnancy in Rheumatoid arthritis and Spondyloarthritis A prospective French study of rheumatoid arthritis (RA) or spondyloarthritis (SpA) patients showed that most maintained stable disease activity during pregnancy, but over one-third flared and https://t.co/MaWx6AZ0JF

Increasing Prevalence of Osteoporosis Research published in Osteoporosis International studied NHANES data showed increasing trends in osteoporosis in the United States of America. https://t.co/KHWdMgjG0P https://t.co/lfXZA9F2JX

• Increasing Prevalence of Osteoporosis | RheumNow

Autoimmune Disease Impact Report Integrated Benefit Institute, a nonprofit independent research organization, has published its 2025 Autoimmune Disease Impact Report, which examines the health and productivity impacts of five prevalent and costly autoimmune conditions: https://t.co/x3l9HIDul8

NP and PA Growth in the USA Forbes has published a thoughtful perspective on the declining number of US physicians and the growth in the number of advanced practice providers or APPs in the US clinical workforce. https://t.co/3Am8ZfEFo1 https://t.co/HeYfHc03Lu https://t.co/6H5wuf5RJ0

• NP and PA Growth in the USA | RheumNow
• NP and PA Growth in the USA | RheumNow

In 2021 the global rheumatoid arthritis market was valued at USD 22.77 billion and is expected to reach USD 33.30 billion by 2030. https://t.co/0vU6QP9JiG https://t.co/a8jXwk3KbK

• https://buff.ly/1rLDehO

Adrenal Dysfunction after Steroids in PMR and GCA Patients JAMA has published a study of PMR and GCA patients who stopped glucocorticoid (GC) therapy and noted a low (1.2%) risk of GC-induced adrenal insufficiency after planned cessation. https://t.co/zQSa8ex9na https://t.co/gkKxHFPuNe

• Adrenal Dysfunction after Steroids in PMR and GCA Patients | RheumNow

Korea National Health Insurance Database review shows that risk of mortality in Behcets patients is 28% higher than gen. population; highest in 1st 12 mos (OR 2.66). Major causes were CA, CVD, GI (viscus rupture), respiratory, & infections. Higher in younger pts. https://t.co/vWJrUN9C0H

MD Anderson Cancer Center study of 1991 RA pts w/ prostate, lung or colon cancer showed TNFi use in 1st 3yrs did NOT affect survival. Use of TNFi vs csDMARDs - nonsign lowering in CRCA (HR 0·72;0·43–1·21), Lung CA (0·70;0·49–1·00), Prostate CA (0·80;0·44–1·44) https://t.co/8zJ0OBWjbm

If COVID was responsible for causing autoimmune Dz (AD), it is possible that Molecular mimicry was in play. Study shows 10nsequence homology between SARS-CoV-2 & AD epitopes; 2) similar MHC binding; 3) of high empirical immunogenicity. https://t.co/WO3gjxhVBw https://t.co/QdqtQMHcpL

• Molecular mimicry impact of the COVID-19 pandemic: Sequence homology between SA…

Researchers have developed a machine learning model capable of predicting rheumatoid arthritis progression from seronegative undifferentiated arthritis. In the KURAMA cohort of 210 SN patients, 57 (27%) progressed to RA. The FNN model excelled with an AUC of 0.924 and 81% https://t.co/b8G2AzMZ7m

Phase 3 RCT shows that SC Abatacept was not effective in treating Active Idiopathic Inflammatory Myopathy: 148 (double-blind) & 133 (OL) pts Rx for 24wks with similar improvement 56% ABA vs 42.5% PBO (P = 0.083); NS at 52 wks & w/ dermatomyositis. https://t.co/InlHJSmiKn https://t.co/mtFQWp3vlb

• Efficacy and Safety of Subcutaneous Abatacept Plus Standard Treatment for Activ…